Back to results
US 2016/0108121 A1Published application
T Cell Regulation
AssigneesThe Johns Hopkins University, St. Jude's Children's Research Hospital, Inc.
InventorsDrew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles Drake, Dario A. Vignali, Creg J. Workman
Life of this patent
Estimating the term…
Abstract
Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.
Claims5
A method for treating a mammal with a cancer, comprising:
- administering to the mammal a first antibody which specifically binds to CD223 protein and inhibits negative T cell regulatory function of CD223;
- and
- administering to the mammal a second antibody which is an anti-cancer antibody.
Dependencies are inferred from the claim text.